Nautilus Biotechnology annual r&d spending
2020
2021
2022
2023
2024
2025
Nautilus Biotechnology R&D Spending Growth & History (NAUT)
Nautilus Biotechnology's r&d spending was $41.1M for fiscal 2025.
View full Nautilus Biotechnology company overviewNautilus Biotechnology annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $41.1M | −$9.4M | −18.56% |
| 2024 | 2024-12-31 | $50.5M | $3.2M | +6.83% |
| 2023 | 2023-12-31 | $47.3M | $9.6M | +25.43% |
| 2022 | 2022-12-31 | $37.7M | $8.3M | +28.35% |
| 2021 | 2021-12-31 | $29.4M | $16.9M | +136.10% |
| 2020 | 2020-12-31 | $12.4M | — | — |
Nautilus Biotechnology quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.6M | −$781,000 | −7.51% |
| Q1 2026 | 2026-03-31 | $9.7M | −$1.8M | −15.85% |
| Q4 2025 | 2025-12-31 | $9.6M | −$3.2M | −25.33% |
| Q3 2025 | 2025-09-30 | $9.6M | −$2.7M | −21.83% |
| Q2 2025 | 2025-06-30 | $10.4M | −$2.0M | −16.42% |
| Q1 2025 | 2025-03-31 | $11.5M | −$1.4M | −10.78% |
| Q4 2024 | 2024-12-31 | $12.8M | $357,000 | +2.86% |
| Q3 2024 | 2024-09-30 | $12.3M | $292,000 | +2.43% |
| Q2 2024 | 2024-06-30 | $12.4M | $524,000 | +4.40% |
| Q1 2024 | 2024-03-31 | $12.9M | $2.1M | +18.87% |
| Q4 2023 | 2023-12-31 | $12.5M | $2.9M | +30.03% |
| Q3 2023 | 2023-09-30 | $12.0M | $2.4M | +25.34% |
| Q2 2023 | 2023-06-30 | $11.9M | $3.1M | +34.51% |
| Q1 2023 | 2023-03-31 | $10.9M | $1.2M | +12.62% |
| Q4 2022 | 2022-12-31 | $9.6M | −$306,000 | −3.09% |
| Q3 2022 | 2022-09-30 | $9.6M | $1.3M | +16.10% |
| Q2 2022 | 2022-06-30 | $8.9M | $2.5M | +38.81% |
| Q1 2022 | 2022-03-31 | $9.7M | $4.8M | +99.75% |
| Q4 2021 | 2021-12-31 | $9.9M | — | — |
| Q3 2021 | 2021-09-30 | $8.2M | $4.9M | +148.54% |
| Q2 2021 | 2021-06-30 | $6.4M | $3.6M | +131.92% |
| Q1 2021 | 2021-03-31 | $4.8M | — | — |
| Q3 2020 | 2020-09-30 | $3.3M | — | — |
| Q2 2020 | 2020-06-30 | $2.8M | — | — |
Nautilus Biotechnology r&d spending trends
Over the last five fiscal years, Nautilus Biotechnology's r&d spending increased from $12.4M to $41.1M, a change of $28.7M. The latest reported quarter, Q2 2026, shows $9.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nautilus Biotechnology source filings ↗